Eukarÿs develops synthetic gene therapies for severe liver disorders, as well as bioporduction tools for recombinant proteins and viruses, all based on the proprietary expression system C3P3

The French Biotechnology Company Eukarÿs SAS exploits the applications of its proprietary C3P3 platform technology, which is used for both therapeutic and non-therapeutic purposes. Its so-called synthetic gene therapy approach voir plus

The French Biotechnology Company Eukarÿs SAS exploits the applications of its proprietary C3P3 platform technology, which is used for both therapeutic and non-therapeutic purposes. Its so-called synthetic gene therapy approach based on its C3P3 system is radically different of those existing to date in terms of efficiency, safety of use, tolerance. Due to the generic and modular nature of synthetic gene therapy, Eukarÿs is building a therapeutic pipeline initially for severe liver diseases. The R&D phase of our first candidate therapy - EUK-LPR - for the prevention of hepatic insufficiency after major liver resection will be finalized T4 2018 with already excellent performances. In addition, Eukarÿs is developing non-therapeutic C3P3 tools for the bioproduction of recombinant proteins and lentiviruses with the aim of marketing them via non-exclusive licensing agreements. voir moins